New data is emerging on the use of Dexcom CGM and its impact on the clinical and psychosocial health for those with type 2 diabetes (T2D). This program will review recently published outcomes that contributed to Medicare expanding coverage for CGM, like Dexcom G7 for the management of people with T2D on basal insulin in the U.S. Additionally, we will examine recent findings on the prevalence of hypoglycemia in Medicare populations, and demonstrate how RT-CGM, like Dexcom G7, may provide support and improve glycemic outcomes for older adults with T2D. Hear from the experts regarding the best practices on implementing Dexcom G7 in clinical practice and learn new strategies to use TIR data to simplify the review of CGM reports. Finally, take a look at recent innovations and connections now available with Dexcom G7 designed to ease the burden of diabetes management.
You must be logged in and own this session in order to